ARCHIVES

MSKCC oncologist settles insider trading case with SEC.

This article is from The Cancer Letter archive.

Vol. 31 No. 41 | November 11, 2005

Download PDF Visit The Full Archive

Related Articles

ODAC Member Critical Of Amgen For Price Incentives.

March 21, 2008

DCT Advisors Approve Grants Program For Trials Of BRMs

March 10, 1995

OMB Reprogramming Ban Criticized

September 20, 1985

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

March 2, 2007

Solomon Garb’s Questions/Answers

December 19, 1980

In Brief: Resolution wasn’t Strong Enough, Reizen Though; Two More chemicals reported Out of Bioassay

June 3, 1977